Pearl Huang, Not Applicable
President & CEO, Dunad Therapeutics
Pearl Huang, Ph.D., has more than 30 years of leadership experience in pharma and biotech and is now the President and CEO of Dunad Therapeutics. Pearl earned a bachelor’s degree in biology from MIT and went on to complete her PhD in molecular biology from Princeton University. She began her professional career as a senior research biochemist at Merck Research Labs in 1990 before moving to DuPont Pharmaceuticals as the director of cancer biology. Huang then joined GlaxoSmithKline as VP of BIology for the MMPD CEDD before returning to Merck to serve as VP and oncology franchise integrator, a strategic role heading up translational medicine to create the then-nascent oncology pipeline. In 2010, Huang co-founded Beigene in China, where she served as Chief Scientific Officer until 2012. She then returned to big pharma, holding leadership roles at GlaxoSmithKline and Roche before joining Cygnal Therapeutics, where she served as President and CEO. She was also a venture partner at Flagship Pioneering, the venture creation firm that founded Cygnal Therapeutics. In addition to her role with Dunad, she is an active member of several boards.